GLP-1 Therapies: How They Work, Who Benefits, and What to Know (2026 Guide)
Everything we wish more patients knew about GLP-1 medications - how they work, who they help, and how to use them as part of a longer-term metabolic plan.
GLP-1 therapies are medications that engage receptors for glucagon-like peptide-1, a gut hormone that signals satiety, slows gastric emptying, and supports insulin signaling. Branded GLP-1, GIP, and triple-agonist medications are FDA-approved for type 2 diabetes or chronic weight management; compounded variants are dispensed by Wells Pharmacy Network only after a licensed clinician evaluation.
How do GLPs work?
GLP-1 (glucagon-like peptide-1) is released from the gut after a meal. Its receptor is found on pancreatic beta cells, on neurons that regulate appetite, and in the gastric wall. Compounds studied in research literature, including semaglutide, tirzepatide, and retatrutide, engage that receptor (and in some cases GIP and glucagon receptors as well) and are studied for their coordinated effects on insulin signaling, appetite, and gastric emptying.
How do clinicians use GLPs?
Beyond appetite
Weight change is the most visible effect described in the research, but other measurable signals - A1c, visceral fat, lipid profiles - are often what clinicians focus on for long-term health. Outcomes vary by individual and are not guaranteed.
Protecting lean mass
Aggressive calorie deficits can cost muscle. Inside a clinician-directed protocol, GLP-related care is paired with resistance-training guidance and, when appropriate, complementary peptides such as MOTS-c or AOD-9604, all decided after a clinician evaluation.
The maintenance plan
GLP-related compounds work while you take them. A clinician-directed program is designed with a deliberate maintenance phase - adjusting dose, building habits, and using diagnostics to track response over time.
What are GLPs studied for?
GLP-1 and incretin co-agonist research spans several adjacent metabolic and cardiovascular endpoints, not just weight.
Type 2 diabetes glycaemic control
GLP-1 receptor agonists are extensively studied for A1c reduction, postprandial glucose excursions, and beta-cell preservation in type 2 diabetes.
Chronic weight management
Trials in adults with obesity have shown sustained body-weight reduction with semaglutide and tirzepatide. Magnitude varies and rebound is common when therapy is stopped without a maintenance plan.
Cardiometabolic risk reduction
Outcome trials such as SELECT and STEP-HFpEF have studied effects on major adverse cardiovascular events and on heart-failure-with-preserved-ejection-fraction symptom burden.
Adjacent metabolic research
MASLD/NASH, polycystic ovary syndrome, and chronic kidney disease are all active research areas for incretin-based therapies. The clinical evidence base is at different stages of maturity in each.
Which ingredients power GLPs protocols?
Wiki entries on individual ingredients used inside GLPs protocols.
Frequently asked questions about GLPs
Is a compounded GLP-1 the same as the branded medication?
No. Compounded preparations are not generic equivalents of branded GLP-1 medications. They are distinct products dispensed by a 503A or 503B compounding pharmacy after an individual clinician prescribes one. They are not FDA-approved as finished drug products.
How long do people typically stay on a GLP-1?
GLP-1 medications work while they are being taken. Many clinicians plan around an induction phase, a maintenance phase, and - when appropriate - a structured taper. Length of therapy depends on goals, response, side-effect profile, and ongoing clinical evaluation.
What about losing muscle on a GLP-1?
Any rapid weight loss carries a risk of losing lean mass. The published research and most clinician protocols emphasise adequate protein intake, regular resistance training, and dose titration that prioritises tolerability and lean-mass preservation.
What are the most common side effects?
Nausea, constipation, and reflux are the most commonly described side effects in trials, especially during dose escalation. Less common but more serious risks (pancreatitis, gallbladder disease, gastroparesis) are part of the labelling for FDA-approved finished products and are part of the clinician-evaluation process.
Will A1c improve faster than weight?
A1c often improves earlier in therapy as insulin signalling responds to the incretin effect, while body-weight change accumulates over months. The two are tracked together because they describe different aspects of metabolic improvement.
Who should not take a GLP-1?
Personal or family history of medullary thyroid carcinoma, MEN2, severe gastroparesis, active pancreatitis, pregnancy, and several other conditions are contraindications or cautions. The clinician evaluation exists specifically to surface these.
Where can I read the source research?
- Wilding JPH et al., NEJM 2021 - STEP 1: Once-weekly semaglutide in adults with overweight or obesity
- Jastreboff AM et al., NEJM 2022 - SURMOUNT-1: Tirzepatide in adults with obesity
- Lincoff AM et al., NEJM 2023 - SELECT: Semaglutide and cardiovascular outcomes in obesity without diabetes
- Kosiborod MN et al., NEJM 2023 - STEP-HFpEF: Semaglutide in HFpEF and obesity
- FDA - Medications containing semaglutide marketed for type 2 diabetes or weight loss
Ready to look at protocols?
Browse the catalog or start a clinician evaluation. Every prescription is reviewed by a licensed clinician.
Browse metabolic protocols →